Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CCR4 | P51679 | 5/20 | 0.31 |
| ▸ | MPI | P34949 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11227327 | 0.77 | NNMT (0.35) | CHRNB2CHRNA4SIRT6KDM4EALDH1A1 | |
| SCHEMBL11223761 | 0.77 | SIRT6 (0.33) | SIRT6KDM4EALDH1A1SMN1; SMN2CCR4 | |
| SCHEMBL29299460 | 0.77 | ALDH1A1 (0.33) | SIRT6KDM4EALDH1A1SMN1; SMN2MPI | |
| SCHEMBL31022760 | 0.77 | POLB (0.36) | CHRNB2CHRNA4SIRT6KDM4EALDH1A1 | |
| SCHEMBL13500438 | 0.77 | POLB (0.36) | CHRNB2CHRNA4SIRT6KDM4EALDH1A1 | |
| SCHEMBL25548420 | 0.76 | NPC1 (0.38) | KDM4EALDH1A1SMN1; SMN2CCR4 | |
| SCHEMBL1315972 | 0.75 | SIRT6 (0.36) | CHRNB2CHRNA4SIRT6ALDH1A1 | |
| SCHEMBL273776 | 0.75 | — | — | |
| SCHEMBL5106649 | 0.74 | MAPKAPK2 (0.32) | SIRT6ALDH1A1CCR4 | |
| SCHEMBL5106652 | 0.74 | CCR4 (0.34) | CCR4CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | CHRNB2 820/4885CHRNA4 615/4885SIRT6 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.